Emergent Biosolutions Inc (EBS) - Net Assets
Based on the latest financial reports, Emergent Biosolutions Inc (EBS) has net assets worth $522.60 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.32 Billion) and total liabilities ($796.00 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Emergent Biosolutions Inc to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $522.60 Million |
| % of Total Assets | 39.63% |
| Annual Growth Rate | N/A |
| 5-Year Change | -67.57% |
| 10-Year Change | -12.35% |
| Growth Volatility | 100.08 |
Emergent Biosolutions Inc - Net Assets Trend (2001–2025)
This chart illustrates how Emergent Biosolutions Inc's net assets have evolved over time, based on quarterly financial data. Also explore Emergent Biosolutions Inc balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Emergent Biosolutions Inc (2001–2025)
The table below shows the annual net assets of Emergent Biosolutions Inc from 2001 to 2025. For live valuation and market cap data, see EBS market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $522.60 Million | +8.24% |
| 2024-12-31 | $482.80 Million | -25.64% |
| 2023-12-31 | $649.30 Million | -53.05% |
| 2022-12-31 | $1.38 Billion | -14.18% |
| 2021-12-31 | $1.61 Billion | +11.37% |
| 2020-12-31 | $1.45 Billion | +32.94% |
| 2019-12-31 | $1.09 Billion | +7.68% |
| 2018-12-31 | $1.01 Billion | +10.80% |
| 2017-12-31 | $912.35 Million | +53.03% |
| 2016-12-31 | $596.21 Million | -9.67% |
| 2015-12-31 | $660.02 Million | +19.31% |
| 2014-12-31 | $553.20 Million | +13.09% |
| 2013-12-31 | $489.17 Million | +10.64% |
| 2012-12-31 | $442.13 Million | +6.10% |
| 2011-12-31 | $416.73 Million | +11.56% |
| 2010-12-31 | $373.56 Million | +53.21% |
| 2009-12-31 | $243.81 Million | +22.31% |
| 2008-12-31 | $199.35 Million | +16.47% |
| 2007-12-31 | $171.16 Million | +23.61% |
| 2006-12-31 | $138.47 Million | +131.80% |
| 2005-12-31 | $59.74 Million | +160.30% |
| 2004-12-31 | $22.95 Million | +452.32% |
| 2002-12-31 | $4.16 Million | +112.87% |
| 2001-12-31 | $-32.30 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Emergent Biosolutions Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 122.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $100.00K | 0.02% |
| Other Comprehensive Income | $-7.50 Million | -1.44% |
| Other Components | $689.80 Million | 131.99% |
| Total Equity | $522.60 Million | 100.00% |
Emergent Biosolutions Inc Competitors by Market Cap
The table below lists competitors of Emergent Biosolutions Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
RCE Capital Berhad
KLSE:9296
|
$423.86 Million |
|
Orient Electric Limited
NSE:ORIENTELEC
|
$423.88 Million |
|
Masoval AS
OL:MAS
|
$424.13 Million |
|
TMK
KLSE:5330
|
$424.30 Million |
|
Shanghai Menon Animal Nutrition Technology Co. Ltd.
SHE:301156
|
$423.77 Million |
|
Globe Trade Centre S.A.
WAR:GTC
|
$423.56 Million |
|
Taimide Tech Inc
TW:3645
|
$423.53 Million |
|
Zumiez Inc
NASDAQ:ZUMZ
|
$423.23 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Emergent Biosolutions Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 482,800,000 to 522,600,000, a change of 39,800,000 (8.2%).
- Net income of 52,600,000 contributed positively to equity growth.
- Share repurchases of 24,900,000 reduced equity.
- Other comprehensive income decreased equity by 2,300,000.
- Other factors increased equity by 14,400,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $52.60 Million | +10.07% |
| Share Repurchases | $24.90 Million | -4.76% |
| Other Comprehensive Income | $-2.30 Million | -0.44% |
| Other Changes | $14.40 Million | +2.76% |
| Total Change | $- | 8.24% |
Book Value vs Market Value Analysis
This analysis compares Emergent Biosolutions Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.99x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-12-31 | $-1.75 | $9.10 | x |
| 2002-12-31 | $0.20 | $9.10 | x |
| 2004-12-31 | $1.12 | $9.10 | x |
| 2005-12-31 | $2.63 | $9.10 | x |
| 2006-12-31 | $5.64 | $9.10 | x |
| 2007-12-31 | $5.77 | $9.10 | x |
| 2008-12-31 | $6.55 | $9.10 | x |
| 2009-12-31 | $7.69 | $9.10 | x |
| 2010-12-31 | $11.35 | $9.10 | x |
| 2011-12-31 | $11.44 | $9.10 | x |
| 2012-12-31 | $12.12 | $9.10 | x |
| 2013-12-31 | $13.32 | $9.10 | x |
| 2014-12-31 | $12.08 | $9.10 | x |
| 2015-12-31 | $13.97 | $9.10 | x |
| 2016-12-31 | $12.08 | $9.10 | x |
| 2017-12-31 | $18.13 | $9.10 | x |
| 2018-12-31 | $19.67 | $9.10 | x |
| 2019-12-31 | $20.77 | $9.10 | x |
| 2020-12-31 | $26.90 | $9.10 | x |
| 2021-12-31 | $29.79 | $9.10 | x |
| 2022-12-31 | $27.60 | $9.10 | x |
| 2023-12-31 | $12.68 | $9.10 | x |
| 2024-12-31 | $9.11 | $9.10 | x |
| 2025-12-31 | $9.22 | $9.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Emergent Biosolutions Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.07%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.08%
- • Asset Turnover: 0.56x
- • Equity Multiplier: 2.52x
- Recent ROE (10.07%) is below the historical average (39.74%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | 0.00% | -1.22% | 1.78x | 0.00x | $2.68 Million |
| 2002 | 875.86% | 46.34% | 3.45x | 5.48x | $35.98 Million |
| 2004 | 49.99% | 13.74% | 1.21x | 3.01x | $9.18 Million |
| 2005 | 26.42% | 12.08% | 1.30x | 1.68x | $9.81 Million |
| 2006 | 16.46% | 14.92% | 0.64x | 1.72x | $8.95 Million |
| 2007 | 13.40% | 12.54% | 0.67x | 1.60x | $5.82 Million |
| 2008 | 10.37% | 11.58% | 0.61x | 1.46x | $747.10K |
| 2009 | 12.91% | 13.26% | 0.68x | 1.43x | $7.02 Million |
| 2010 | 13.99% | 18.07% | 0.57x | 1.35x | $14.75 Million |
| 2011 | 5.56% | 8.42% | 0.50x | 1.32x | $-18.41 Million |
| 2012 | 5.33% | 8.35% | 0.50x | 1.28x | $-20.61 Million |
| 2013 | 6.36% | 9.96% | 0.50x | 1.28x | $-17.83 Million |
| 2014 | 6.64% | 9.08% | 0.43x | 1.71x | $-18.58 Million |
| 2015 | 9.53% | 12.85% | 0.47x | 1.58x | $-3.13 Million |
| 2016 | 8.69% | 10.60% | 0.50x | 1.63x | $-7.82 Million |
| 2017 | 9.05% | 14.73% | 0.52x | 1.17x | $-8.63 Million |
| 2018 | 6.20% | 8.01% | 0.35x | 2.21x | $-38.39 Million |
| 2019 | 5.01% | 4.93% | 0.48x | 2.14x | $-54.35 Million |
| 2020 | 21.13% | 19.39% | 0.55x | 1.99x | $161.10 Million |
| 2021 | 13.62% | 12.38% | 0.60x | 1.84x | $58.35 Million |
| 2022 | -16.18% | -19.97% | 0.35x | 2.29x | $-362.10 Million |
| 2023 | -117.13% | -72.48% | 0.58x | 2.81x | $-825.43 Million |
| 2024 | -39.48% | -18.26% | 0.75x | 2.88x | $-238.88 Million |
| 2025 | 10.07% | 7.08% | 0.56x | 2.52x | $340.00K |
Industry Comparison
This section compares Emergent Biosolutions Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $196,265,727
- Average return on equity (ROE) among peers: -56.95%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Emergent Biosolutions Inc (EBS) | $522.60 Million | 0.00% | 1.52x | $423.84 Million |
| Aurora Cannabis Inc (ACB) | $605.09 Million | 0.26% | 0.40x | $197.35 Million |
| Akanda Corp (AKAN) | $-3.83 Million | 0.00% | 0.00x | $1.51 Million |
| Akebia Ther (AKBA) | $32.61 Million | -16.39% | 10.55x | $340.21 Million |
| Alkermes Plc (ALKS) | $1.09 Billion | -18.11% | 0.66x | $4.62 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-25.36 Million | 0.00% | 0.00x | $1.78 Billion |
| Amphastar P (AMPH) | $427.53 Million | 11.45% | 0.37x | $959.02 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-186.87 Million | 0.00% | 0.00x | $3.81 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $20.01 Million | -419.73% | 172.53x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $5.40 Million | -25.93% | 0.43x | $202.62 Million |
| ANI Pharmaceuticals Inc (ANIP) | $2.63 Million | -101.06% | 0.31x | $1.80 Billion |
About Emergent Biosolutions Inc
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intrav… Read more